Literature DB >> 15023282

Therapeutic Strategies for Cardiogenic Shock.

Naji F. Yazbek1, Neal S. Kleiman.   

Abstract

Cardiogenic shock is a devastating consequence of acute myocardial infarction; it is associated with an extremely high mortality. Treatment strategies should be focused on prompt reperfusion, as well as hemodynamic support. The optimal approach for therapy is emergent angiography and revascularization using percutaneous coronary intervention or coronary artery bypass surgery, with the assistance of intra-aortic balloon pump counterpulsation. Several adjunctive pharmacologic agents, particularly inotropic drugs and vasopressors, are also helpful for hemodynamic support. However, these agents have not been shown to provide a survival benefit, and their use is primarily based on clinical experience.

Entities:  

Year:  2004        PMID: 15023282     DOI: 10.1007/s11936-004-0012-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  55 in total

1.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

2.  Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation.

Authors:  D Hasdai; R A Harrington; J S Hochman; R M Califf; A Battler; J W Box; M L Simoons; J Deckers; E J Topol; D R Holmes
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

3.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

4.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; E M Antman; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B Riegel; R O Russell; E E Smith; W D Weaver; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; A Garson; G Gregoratos; T J Ryan; S C Smith
Journal:  J Am Coll Cardiol       Date:  1999-09       Impact factor: 24.094

5.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Authors:  J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

6.  Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure.

Authors:  J Gage; H Rutman; D Lucido; T H LeJemtel
Journal:  Circulation       Date:  1986-08       Impact factor: 29.690

Review 7.  Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock.

Authors:  M D Hibbard; D R Holmes; K R Bailey; G S Reeder; J F Bresnahan; B J Gersh
Journal:  J Am Coll Cardiol       Date:  1992-03-01       Impact factor: 24.094

8.  Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location.

Authors:  B I Jugdutt; J W Warnica
Journal:  Circulation       Date:  1988-10       Impact factor: 29.690

9.  Emergency coronary bypass for cardiogenic shock.

Authors:  R A Guyton; J M Arcidi; D A Langford; D C Morris; H A Liberman; C R Hatcher
Journal:  Circulation       Date:  1987-11       Impact factor: 29.690

10.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.